The role of nutrition, nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension

Alternative Therapies in Health and Medicine

Volumn 19, Issue SUPPL.1, 2013, Pages 32-49

  Houston, Mark C ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT THOMAS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; MINERAL; VITAMIN;

BLOOD PRESSURE; EXERCISE; HUMAN; HYPERTENSION; LIFESTYLE; METHODOLOGY; PRIMARY PREVENTION; REVIEW;

ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOOD PRESSURE; EXERCISE; HUMANS; HYPERTENSION; LIFE STYLE; MINERALS; PRIMARY PREVENTION; VITAMINS;

EID: 84884277476     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (256)

1. Houston MC. Treatment of hypertension with nutraceuticals, vitamins, antioxidants and minerals. Expert Rev Cardiovasc Ther. 2007;5(4):681-691.
2. Eaton SB, Eaton SB III, Konner MJ. Paleolithic nutrition revisited: a twelveyear retrospective on its nature and implications. Eur J Clin Nutr. 1997;51(4):207-216.
3. Layne J, Majkova Z, Smart EJ, Toborek M, Hennig B. Caveolae: a regulatory platform for nutritional modulation of inflammatory diseases. J Nutr Biochem. 2011;22(9):807-811.
4. Dandona P, Ghanim H, Chaudhuri A, Dhindsa S, Kim SS. Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. Exp Mol Med. 2010;42(4):245-253.
5. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
6. Kizhakekuttu TJ, Widlansky ME. Natural antioxidants and hypertension: promise and challenges. Cardiovasc Ther. 2010;28(4):e20-e32.
7. Houston MC. New insights and approaches to reduce end-organ damage in the treatment of hypertension: subsets of hypertension approach. Am Heart J. 1992;123(5):1337-1367.
8. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in six European countries, Canada, and the United States. JAMA. 2003;289(18):2363-2369.
9. Nayak DU, Karmen C, Frishman WH, Vakili BA. Antioxidant vitamins and enzymatic and synthetic oxygen-derived free radical scavengers in the prevention and treatment of cardiovascular disease. Heart Dis. 2001;3(1):28-45.
10. Kitiyakara C, Wilcox CS. Antioxidants for hypertension. Curr Opin Nephrol Hypertens. 1998;7(5):531-538.
11. Russo C, Olivieri O, Girelli D, et al. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens. 1998;16(9):1267-1271.
12. Tse WY, Maxwell SR, Thomason H, et al. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J Hum Hypertens. 1994;8(11):843-849.
13. Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR. Combination oral antioxidant supplementation reduces blood pressure. Clin Sci (Lond). 1997;92(4):361-365.
14. Dhalla NS, Temsah RM, Netticadam T. The role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18(6):655-673.
15. Saez G, Tormos MC, Giner V, et al. Oxidative stress and enzymatic antioxidant mechanisms in essential hypertension. Am J Hypertens. 2001;14:248A. doi:10.1016/S0895-7061(01)01983-5.
16. Ghanem FA, Movahed A. Inflammation in high blood pressure: a clinician perspective. J Am Soc Hypertens. 2007;1(2):113-119.
17. Amer MS, Elawam AE, Khater MS, Omar OH, Mabrouk RA, Taha HM. Association of high-sensitivity C-reactive protein with carotid artery intima-media thickness in hypertensive older adults. J Am Soc Hypertens. 2011;5(5):395-400.
18. Kvakan H, Luft FC, Muller DN. Role of the immune system in hypertensive target organ damage. Trends Cardiovasc Med. 2009;19(7):242-246.
19. Rodriguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson RJ. Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2012;39(1):96-103.
20. Mansego ML, Solar Gde M, Alonso MP, et al. Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J Hypertens. 2011;29(3):492-500.
21. Vongpatanasin W, Thomas GD, Schwartz R, et al. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007;115(8):1020-1028.
22. Razzouk L, Muntner P, Bansilal S, et al. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am Heart J. 2009;158(2):277-283.
23. Tian N, Penman AD, Mawson AR, Manning RD Jr, Flessner MF. Association between circulating specific leukocyte types and blood pressure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Hypertens. 2010;4(6):272-283.
24. Muller DN, Kvakan H, Luft FC. Immune-related effects in hypertension and target-organ damage. Curr Opin Nephrol Hypertens. 2011;20(2):113-117.
25. Leibowitz A, Schiffin EL. Immune mechanisms in hypertension. Curr Hypertens Rep. 2011;13(6):465-472.
26. Houston MC. The importance of potassium in managing hypertension. Curr Hypertens Rep. 2011;13(4):309-317.
27. Berdanier CD. Nutrient-gene interactions. In: Ziegler EE, Filer LJ Jr, eds. Present Knowledge in Nutrition. 7th ed. Washington, DC: ILSI Press; 1996:574-580.
28. Talmud PJ, Waterworth DM. In-vivo and in-vitro nutrient-gene interactions. Curr Opin Lipidol. 2000;11(1):31-36.
29. Broadhurst CL. Balanced intakes of natural triglycerides for optimum nutrition: an evolutionary and phytochemical perspective. Med Hypotheses. 1997;49(3):247-261.
30. Kotchen TA, McCarron DA. Dietary electrolytes and blood pressure: a statement for healthcare professionals from the American Heart Association Nutrition Committee. Circulation. 1998;98(6):613-617.
31. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr. 1997;65(2)(suppl):643S-651S.
32. Svetkey LP, Sacks FM, Obarzanek E, et al. The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. J Am Diet Assoc. 1999;99(8)(suppl):S96-S104.
33. Messerli FH, Schmieder RE, Weir MR. Salt: a perpetrator of hypertensive target organ disease? Arch Intern Med. 1997;157(21):2449-2452.
34. Kawasaki T, Delea CS, Bartter FC, Smith H. The effect of high-sodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension. Am J Med. 1978;64(2):193-198.
35. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27(3, pt 2):481-490.
36. Morimoto A, Uzu T, Fujii T, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997;350(9093):1734-1737.
37. Houston MC. Nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension. Prog Cardiovasc Dis. 2005;47(6):396-449.
38. Houston MC. Nutrition and nutraceutical supplements in the treatment of hypertension. Exper Rev Cardiovasc Ther. 2010;8(6):821-833.
39. Kanbay M, Chen Y, Solak Y, Sanders PW. Mechanisms and consequences of salt sensitivity and dietary salt intake. Curr Opin Nephrol Hypertens. 2011;20(1):37-43.
40. Oberleithner H, Callies C, Kusche-Vihrog K, et al. Potassium softens vascular endothelium and increases nitric oxide release. Proc Natl Acad Sci USA. 2009;106(8):2829-2834.
41. Fels J, Oberleithner H, Kusche-Vihrog K. Menage a trois: aldosterone, sodium and nitric oxide in vascular endothelium. Biochim Biophys Acta. 2010;1802(12):1193-1202.
42. Toda N, Arakawa K. Salt-induced hemodynamic regulation mediated by nitric oxide. J Hypertens. 2011;29(3):415-424.
43. Foulquier S, Dupuis F, Perrin-Sarrado C, et al. High salt intake abolishes AT(2)-mediated vasodilation of pial arterioles in rats. J Hypertens. 2011;29(7):1392-1399.
44. Yang Q, Liu T, Kuklina EV, et al. Sodium and potassium intake and mortality among US adults: prospective data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2011;171(13):1183-1191.
45. Houston MC, Harper KJ. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. J Clin Hypertens (Greenwich). 2008;10(7) (suppl 2):3-11.
46. Whelton PK, He J. Potassium in preventing and treating high blood pressure. Semin Nephrol. 1999;19(5):494-499.
47. Gu D, He J, Wu X, Duan X, Whelton PK. Effect of potassium supplementation on blood pressure in Chinese: a randomized, placebo-controlled trial. J Hypertens. 2001;19(7):1325-1331.
48. Widman L, Wester PO, Stegmayr BK, Wirell M. The dose-dependent reduction in blood pressure through administration of magnesium: a double blind placebo controlled cross-over study. Am J Hypertens. 1993;6(1):41-45.
49. Laurant P, Touyz RM. Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension. J Hypertens. 2000;18(9):1177-1191.
50. Houston M. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2011;13(11):843-847.
51. McCarron DA. Role of adequate dietary calcium intake in the prevention and management of salt-sensitive hypertension. Am J Clin Nutr. 1997;65(2) (suppl):712S-716S.
52. Resnick LM. Calcium metabolism in hypertension and allied metabolic disorders. Diabetes Care. 1991;14(6):505-520.
53. Garcia Zozaya JL, Padilla Viloria M. Alterations of calcium, magnesium, and zinc in essential hypertension: their relation to the renin-angiotensin-aldosterone system [in Spanish]. Invest Clin. 1997;38(suppl 2):27-40.
54. Shahbaz AU, Sun Y, Bhattacharya SK, et al. Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies. J Hypertens. 2010;28(suppl 1):S25-S32.
55. Bergomi M, Rovesti S, Vinceti M, Vivoli R, Caselgrandi E, Vivoli G. Zinc and copper status and blood pressure. J Trace Elem Med Biol. 1997;11(3):166-169.
56. Stamler J, Elliott P, Kesteloot H, et al. Inverse relation of dietary protein markers with blood pressure: findings for 10,020 men and women in the INTERSALT Study: INTERSALT Cooperative Research Group: INTERnational study of SALT and blood pressure. Circulation. 1996;94(7):1629-1634.
57. Altorf-van der Kuil W, Engberink MF, Brink EJ, et al. Dietary protein and blood pressure: a systematic review. PLoS One. 2010;5(8);e12102.
58. Jenkins DJ, Kendall CW, Faulkner DA, et al. Long-term effects of a plant-based dietary portfolio of cholesterol-lowering foods on blood pressure. Eur J Clin Nutr. 2008;62(6):781-788.
59. Elliott P, Dennis B, Dyer AR, et al. Relation of dietary protein (total, vegetable, animal) to blood pressure: INTERMAP epidemiologic study. Paper presented at: 18th Scientific Meeting of the International Society of Hypertension; August 20-24, 2000; Chicago, IL.
60. He J, Wofford MR, Reynolds K, et al. Effect of dietary protein supplementation on blood pressure: a randomized, controlled trial. Circulation. 2011;124(5);589-595.
61. FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. J Nutr. 2004:134(4):980S-988S.
62. Pins JJ, Keenan JM. Effects of whey peptides on cardiovascular disease risk factors. J Clin Hypertens (Greenwich). 2006;8(11):775-782.
63. Aihara K, Kajimoto O, Hirata H, Takahashi R, Nakamura Y. Effect of powdered fermented milk With Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr. 2005;24(4):257-265.
64. Germino FW, Neutel J, Nonaka M, Hendler SS. The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives. J Clin Hypertens (Greenwich). 2010;12(3):153-159.
65. Geleijnse JM, Engberink MF. Lactopeptides and human blood pressure. Curr Opin Lipidol. 2010;21(1):58-63.
66. Pins J, Keenan J. The antihypertensive effects of a hydrolyzed whey protein supplement. Cardiovasc Drugs Ther. 2002;16(suppl 1):68. Abstract P370.
67. Zhu CF, Li GZ, Peng HB, Zhang F, Chen Y, Li Y. Therapeutic effects of marine collagen peptides on Chinese patients with type 2 diabetes mellitus and primary hypertension. Am J Med Sci. 2010;340(5):360-366.
68. De Leo F, Panarese S, Gallerani R, Ceci LR. Angiotensin converting enzyme (ACE) inhibitory peptides: production and implementation of functional food. Curr Pharm Des. 2009;15(31):3622-3643.
69. Lordan S, Ross RP, Stanton C. Marine bioactives as functional food ingredients: potential to reduce the incidence of chronic diseases. Mar Drugs. 2011;9(6):1056-1100.
70. Kawasaki T, Seki E, Osajima K, et al. Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. J Hum Hypertens. 2000;14(8):519-523.
71. Kawasaki T, Jun CJ, Fukushima Y, et al. Antihypertensive effect and safety evaluation of vegetable drink with peptides derived from sardine protein hydrolysates on mild hypertensive, high-normal and normal blood pressure subjects [in Japanese]. Fukuoka Igaku Zasshi. 2002:93(10):208-218.
72. Yang G, Shu XO, Jin F, et al. Longitudinal study of soy food intake and blood pressure among middle-aged and elderly Chinese women. Am J Clin Nutr. 2005;81(5):1012-1017.
73. Teede HJ, Giannopoulos D, Dalais FS, Hodgson J, McGrath BP. Randomised, controlled, cross-over trial of soy protein with isoflavones on blood pressure and arterial function in hypertensive patients. J Am Coll Nutr. 2006;25(6):533-540.
74. Welty FK, Lee KS, Lew NS, Zhou JR. Effect of soy nuts on blood pressure and lipid levels in hypertensive, prehypertensive and normotensive postmenopausal women. Arch Intern Med. 2007;167(10):1060-1067.
75. Rosero Arenas MA, Rosero Arenas E, Portaceli Arminana MA, Garcia Garcia MA. Usefulness of phyto-oestrogens in reduction of blood pressure: systematic review and meta-analysis [in Spanish]. Aten Primaria. 2008;40(4):177-186.
76. Nasca MM, Zhou JR, Welty FK. Effect of soy nuts on adhesion molecules and markers of inflammation in hypertensive and normotensive postmenopausal women. Am J Cardiol. 2008;102(1):84-86.
77. He J, Gu D, Wu X, et al. Effect of soybean protein on blood pressure: a randomized, controlled trial. Ann Intern Med. 2005:143(1):1-9.
78. Hasler CM, Kundrat S, Wool D. Functional foods and cardiovascular disease. Curr Atheroscler Rep. 2000;2(6):467-475.
79. Tikkanen MJ, Adlercreutz H. Dietary soy-derived isoflavone phytoestrogens: could they have a role in coronary heart disease prevention? Biochem Pharmacol. 2000;60(1):1-5.
80. Begg DP, Sinclair AJ, Stahl LA, Garg ML, Jois M, Weisinger RS. Dietary protein level interacts with omega-3 polyunsaturated fatty acid deficiency to induce hypertension. Am J Hypertens. 2010;23(2):125-128.
81. Morris MC. Dietary fats and blood pressure. J Cardiovasc Risk. 1994;1(1):21-30.
82. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension. 1999;34(2):253-260.
83. Bonaa KH, Bjerve KS, Straume B, Gram IT, Thelle D. Effect of eicosapentaenoic and docosahexanoic acids on blood pressure in hypertension: a population-based intervention trial from the Tromso study. N Engl J Med. 1990;322(12):795-801.
84. Mori TA, Burke V, Puddey I, et al. The effects of omega 3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens. 2009;27(9):1863-1872.
85. Ueshima H, Stamler J, Elliot P, et al; INTERMAP Research Group. Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure: INTERMAP study. Hypertension. 2007;50(2):313-319.
86. Mori TA. Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol. 2006:33(9):842-846.
87. Liu JC, Conklin SM, Manuck SB, Yao JK, Muldoon MF. Long-chain omega-3 fatty acids and blood pressure. Am J Hypertens. 2011;24(10):1121-1126.
88. Engler MM, Schambelan M, Engler MB, Ball DL, Goodfriend TL. Effects of dietary gamma-linolenic acid on blood pressure and adrenal angiotensin receptors in hypertensive rats. Proc Soc Exp Biol Med. 1998;218(3):234-237.
89. Sagara M, Njelekela M, Teramoto T, Taquchi et al. Effects of docosahexaenoic acid supplementation on blood pressure, heart rate, and serum lipids in Scottish men with hypertension and hypercholesterolemia. Int J Hypertens. March 2011;2011:809198.
90. Mori TA, Burke V, Puddey I, et al. The effects of omega-3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens. 2009;27(9):1863-1872.
91. Chin JP. Marine oils and cardiovascular reactivity. Prostaglandins Leukot Essent Fatty Acids. 1994;50(5):211-222.
92. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376(9740):540-550.
93. Ferrara LA, Raimondi AS, d'Episcopo L, Guida L, Dello Russo A, Marotta T. Olive oil and reduced need for antihypertensive medications. Arch Intern Med. 2000;160(6):837-842.
94. Perona JS, Canizares J, Montero E, Sanchez-Dominquez JM, Catala A, Ruiz-Gutierrez V. Virgin olive oil reduces blood pressure in hypertensive elderly subjects. Clin Nutr. 2004;23(5):1113-1121.
95. Perona JS, Montero E, Sanchez-Dominquez JM, Canizares J, Garcia M, Ruiz-Gutierrez V. Evaluation of the effect of dietary virgin olive oil on blood pressure and lipid composition of serum and low-density lipoprotein in elderly type 2 diabetic subjects. J Agric Food Chem. 2009;57(23):11427-11433.
96. Lopez-Miranda J, Perez-Jimenez F, Ros E, et al. Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaen and Cordoba (Spain) 2008. Nutr Metab Cardiovasc Dis. 2010;20(4):284-294.
97. Susalit E, Agus N, Effendi I, et al. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril. Phytomedicine. 2011;18(4):251-258.
98. Thomsen C, Rasmussen OW, Hansen KW, Vesterlund M, Hermansen K. Comparison of the effects on the diurnal blood pressure, glucose, and lipid levels of a diet rich in monounsaturated fatty acids with a diet rich in polyunsaturated fatty acids in type 2 diabetic subjects. Diabet Med. 1995;12(7):600-606.
99. He J, Whelton PK. Effect of dietary fiber and protein intake on blood pressure: a review of epidemiologic evidence. Clin Exp Hypertens. 1999;21(5-6):785-796.
100. Pruijm M, Wuerzer G, Forni V, Bochud M, Pechere-Bertschi A, Burnier M. Nutrition and hypertension: more than table salt [in French]. Rev Med Suisse. 2010;6(262):1715-1720, vi.
101. Simons S, Wollersheim H, Thien T. A systematic review on the influence of trial quality on the effects of garlic on blood pressure. Neth J Med. 2009;67(6):212-219.
102. Reinhart KM, Coleman CI, Teevan C, Vacchani P, White CM. Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. Ann Pharmacother. 2008:42(12):1766-1771.
103. Ried K, Frank OR, Stocks NP. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial. Maturitas. 2010;67(2):144-150.
104. Hodgson JM, Puddey IB, Burke V, Beilin LJ, Jordan N. Effects on blood pressure of drinking green and black tea. J Hypertens. 1999;17(4):457-463.
105. Wahabi HA, Alansary LA, Al-Sabban AH, Glasziuo P. The effectiveness of Hibiscus sabdariffa in the treatment of hypertension: a systematic review. Phytomedicine. 2010;17(2):83-86.
106. Kurita I, Maeda-Yamamoto M, Tachibana H, Kamei M. Antihypertensive effect of Benifuuki tea containing O-methylated EGCG. J Agric Food Chem. 2010;58(3):1903-1908.
107. McKay DL, Chen CY, Saltzman E, Blumberg JB. Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults. J Nutr. 2010;140(2):298-303.
108. Suetsuna K, Nakano T. Identification of an antihypertensive peptide from peptic digest of wakame (Undaria pinnatifida). J Nutr Biochem. 2000;11(9):450-454.
109. Nakano T, Hidaka H, Uchida J, Nakajima K, Hata Y. Hypotensive effects of wakame. J Jpn Soc Clin Nutr. 1998;20:92.
110. Krotkiewski M, Aurell M, Holm G, Grimby G, Szckepanik J. Effects of a sodiumpotassium ion-exchanging seaweed preparation in mild hypertension. Am J Hypertens. 1991;4(6):483-488.
111. Sato M, Oba T, Yamaguchi T, et al. Antihypertensive effects of hydrolysates of wakame (Undaria pinnatifida) and their angiotnesin-I-converting enzyme inhibitory activity. Ann Nutr Metab. 2002;46(6):259-267.
112. Sato M, Hosokawa T, Yamaguchi T, Nakano T, Muramoto K, Kahara T, Funayama K, KobayashiA, and Nakano T. Angiotensin I-converting enzyme inhibitory peptides derived from wakame (Undaria pinnatifida) and their antihypertensive effect in spontaneously hypertensive rats. J Agric Food Chem. 2002;50(21):6245-6252.
113. Sherman DL, Keaney JF Jr, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension. 2000;35(4):936-941.
114. Ness AR, Khaw KT, Bingham S, Day NE. Vitamin C status and blood pressure. J Hypertens. 1996;14(4):503-508.
115. Duffy SJ, Gokce N, Holbrook M, et al. Treatment of hypertension with ascorbic acid. Lancet. 1999;354(9195):2048-2049.
116. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 1992;3(3):194-202.
117. Block G, Jensen CD, Norkus EP, Hudes M, Crawford PB. Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young Black and White women. Nut J. Dec 2008;7:35.
118. Hatzitolios A, Iliadis F, Katsiki N, Baltatzi M. Is the anti-hypertensive effect of dietary supplements via aldehydes reduction evidence based? A systemic review. Clin Exp Hypertens. 2008:30(7):628-639.
119. Mahajan AS, Babbar R, Kansal N, Agarwal SK, Ray PC. Antihypertensive and antioxidant action of amlodipine and vitamin C in patients of essential hypertension. J Clin Biochem Nutr. 2007;40(2):141-147.
120. Leclerc PC, Proulx CD, Arquin G, et al. Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II. Am J Hypertens. 2008;21(1):67-71.
121. Plantinga Y, Ghiadoni L, Magagna A, et al. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens. 2007;20(4):392-397.
122. Sato K, DohiY, Kojima M, et al. Effects of ascorbic acid on ambulatory blood pressure in elderly patients with refractory hypertension. Arzneimittelforschung. 2006;56(7):535-540.
123. Block G, Mangels AR, Norkus EP, Patterson BH, Levander OA, Taylor PR. Ascorbic acid status and subsequent diastolic and systolic blood pressure. Hypertension. 2001;37(2):261-267.
124. McRae MP. Is vitamin C an effective antihypertensive supplement? A review and analysis of the literature. J Chiropr Med. 2006;5(2):60-64.
125. Simon JA. Vitamin C and cardiovascular disease: a review. J Am Coll Nutr. 1992;11(2):107-125.
126. Ness AR, Chee D, Elliott P. Vitamin C and blood pressure-an overview. J Hum Hypertens. 1997;11(6):343-350.
127. Trout DL. Vitamin C and cardiovascular risk factors. Am J Clin Nutr. 1991;53(1) (suppl):322S-325S.
128. Fulwood R, Johnson CL, Bryner JD; National Center for Health Statistics. Hematological and nutritional biochemistry reference data for persons 6 months-74 years of age: United States, 1976-80. Vital Health Stat 11. 1982;(232):i-vi, 1-173.
129. Ward NC, Wu JH, Clarke MW, et al. The effect of vitamin E on blood pressure in individuals with type 2 diabetes. J Hypertens. 2007;25(1):227-234.
130. Murray ED Jr, Wechter WJ, Kantoci D, et al. Endogenous natriuretic factors 7: biospecificity of a natriuretic gamma-tocopherol metabolite LLU-alpha. J Pharmacol Exp Ther. 1997;282(2):657-662.
131. Gray B, Swick J, Ronnenberg AG. Vitamin E and adiponectin: proposed mechanism for vitamin E-induced improvement in insulin sensitivity. Nutr Rev. 2011;69(3):155-161.
132. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens. 1995;8(9):894-901.
133. Bednarski R, Donderski R, Manitius J. Role of vitamin D3 in arterial blood pressure control [in Polish]. Pol Merkur Lekarski. 2007;23(136):307-310.
134. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229-238.
135. Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD. Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations? Am J Med. 2010;123(4):335-341.
136. Rosen CJ. Clinical practice: vitamin D insufficiency. N Engl J Med. 2011;364(3):248-254.
137. Boldo A, Campbell P, Luthra P, White WB. Should the concentration of vitamin D be measured in all patients with hypertension? J Clin Hypertens (Greenwich). 2010;12(3):149-152.
138. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307-314.
139. Moyano Peregrin C, Lopez Rodriguez F, Castilla Castellano Mdel M. Vitamin D and hypertension [in Spanish]. Med Clin (Barc). 2012;138(9):397-401.
140. Motiwala SR, Wang TJ. Vitamin D and cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20(4):345-353.
141. Cosenso-Martin LN, Vilela-Martin JF. Is there an association between vitamin D and hypertension? Recent Pat Cardiovasc Drug Discov. 2011;6(2):140-147.
142. Bhandari SK, Pashayan S, Liu IL, et al. 25-hydroxyvitamin D levels and hypertension rates. J Clin Hypertens (Greenwich). 2011;13(3):170-177.
143. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86(4):1633-1637.
144. Keniston R, Enriquez J Sr. Relationship between blood pressure and plasma vitamin B6 levels in healthy middle-aged adults. Ann N Y Acad Sci. May 1990;585:499-501.
145. Aybak M, Sermet A, Ayyildiz MO, Karakilcik AZ. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung. 1995;45(12):1271-1273.
146. Paulose CS, Dakshinamurti K, Packer S, Stephens NL. Sympathetic stimulation and hypertension in the pyridoxine-deficient adult rat. Hypertension. 1988;11(4):387-391
147. Dakshinamurti K, Lal KJ, Ganguly PK. Hypertension, calcium channel and pyridoxine (vitamin B6). Mol Cell Biochem. 1998;188(1-2):137-148.
148. Moline J, Bukharovich IF, Wolff MS, Phillips R. Dietary flavonoids and hypertension: is there a link? Med Hypotheses. 2000;55(4):306-309.
149. Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol. 1994;139(12):1180-1189.
150. Karatzi KN, Papamichael CM, Karatzis EN, et al. Red wine acutely induces favorable effects on wave reflections and central pressures in coronary artery disease patients. Am J Hypertens. 2005;18(9, pt 1):1161-1167.
151. Biala A, Tauriainen E, Siltanen A, et al. Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Blood Press. 2010;19(3):196-205.
152. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2011;21(11):851-856.
153. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur J Pharmacol. 2011;667(1-3):258-264.
154. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77(6):1053-1063.
155. Paran E, Engelhard YN. Effect of lycopene, an oral natural antioxidant on blood pressure. J Hypertens. 2001;19:S74. Abstract P-1.204.
156. Engelhard YN, Gazer B, Paran E. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebocontrolled pilot study. Am Heart J. 2006;151(1):100.
157. Paran E, Novack V, Engelhard YN, Hazan-Halevy I. The effects of natural antioxidants from tomato extract in treated but uncontrolled hypertensive patients. Cardiovasc Drugs Ther. 2009;23(2):145-151.
158. Ried K, Frank OR, Stocks NP. Dark chocolate or tomato extract for prehypertension: a randomised controlled trial. BMC Complement Altern Med. July 2009;9:22.
159. Paran E, Engelhard Y. Effect of tomato's lycopene on blood pressure, serum lipoproteins, plasma homocysteine and oxidative stress markers in grade I hypertensive patients. Am J Hypertens. 2001;14:141A. Abstract P-333.
160. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9(2-4):273-284.
161. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressure and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens. 1999;13(3):203-208.
162. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebocontrolled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. 2001;94(11):1112-1117.
163. Rosenfeldt FL, Haas SJ, Krum H, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21(4):297-306.
164. Ankola DD, Viswanad B, Bhardwaj V, Ramarao P, Kumar MN. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? Eur J Pharm Biopharm. 2007;67(2):361-369.
165. McMackin CJ, Widlansky ME, Hamburg NM, et al. Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich). 2007;9(4):249-255.
166. Salinthone S, Schillace RV, Tsang C, Regan JW, Burdette DN, Carr DW. Lipoic acid stimulates cAMP production via G protein-coupled receptor-dependent and independent mechanisms. J Nutr Biochem. 2011;22(7):681-690.
167. Rahman ST, Merchant N, Hague T, Wahi et al. The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: results from the QUALITY study. J Cardiovasc Pharmacol Ther. 2012;17(2):139-145.
168. Huang YD, Li N, Zhang WG, et al. The effect of oral alpha-lipoic acid in overweight/obese individuals on brachial-ankle pulse wave velocity and supine blood pressure: a randomized, crossover, double-blind, placebo-controlled trial [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2011;32(3):290-296.
169. Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Prac. 2001;52(3):175-183.
170. Ying Z, Kherada N, Farrar B, et al. Lipoic acid effects on established atherosclerosis. Life Sci. 2010;86(3-4):95-102.
171. Siani A, Pagano E, Iacone R, Iacoviello L, Scopacasa F, Strazzullo P. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens. 2000;13(5, pt 1):547-551.
172. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20(suppl 12):S60-S62.
173. Ruiz-Hurtado G, Delgado C. Nitric oxide pathway in hypertrophied heart: new therapeutic uses of nitric oxide donors. J Hypertens. Sep 2010;28(suppl 1):S56-S61.
174. Sonmez A, Celebi G, Erdem G, et al. Plasma apelin and ADMA levels in patients with essential hypertension. Clin Exp Hypertens. 2010;32(3):179-183.
175. Michell DL, Andrews KL, Chin-Dusting JP. Endothelial dysfunction in hypertension: the role of arginase. Front Biosci (Schol Ed). 2011;3:946-960.
176. Rajapakse NW, Mattson DL. Role of L-arginine in nitric oxide production in health and hypertension. Clin Exp Pharmacol Physiol. 2009;36(3):249-255.
177. Tsioufis C, Dimitriadis K, Andrikou E, et al. ADMA, C-reactive protein and albuminuria in untreated essential hypertension: a cross-sectional study. Am J Kidney Dis. 2010;55(6):1050-1059.
178. Facchinetti F, Saade GR, Neri I, Pizzi C, Longo M, Volpe A. L-arginine supplementation in patients with gestational hypertension: a pilot study. Hypertens Pregnancy. 2007;26(1):121-130.
179. Neri I, Monari F, Sqarbi L, Berardi A, Masellis G, Facchinetti F. L-arginine supplementation in women with chronic hypertension: impact on blood pressure and maternal and neonatal complications. J Matern Fetal Neonatal Med. 2010;23(12):1456-1460.
180. Martina V, Masha A, Gigliardi VR, et al. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care. 2008;31(5):940-944.
181. Ast J, Jablecka A, Bogdanski P, Smolarek I, Krauss H, Chmara E. Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Med Sci Monit. 2010;16(5): CR266-CR271.
182. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infraction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006; 295(1):58-64.
183. Feringa HH, Laskey DA, Dickson JE, Coleman CI. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. J Am Diet Assoc. 2011;111(8):1173-1181.
184. Sivaprakasapillai B, Edirishinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism. 2009:58(12):1743-1746.
185. Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992;72(1):101-163.
186. Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 1987;75(3):525-532.
187. Huxtable RJ, Sebring LA. Cardiovascular actions of taurine. Prog Clin Biol Res. 1983;125:5-37.
188. Tanabe Y, Urata H, Kiyonaga A, et al. Changes in serum concentrations of taurine and other amino acids in clinical antihypertensive exercise therapy. Clin Exp Hypertens A. 1989;11(1):149-165.
189. Yamori Y, Taguchi T, Mori H, Mori M. Low cardiovascular risks in the middle aged males and females excreting greater 24-hour urinary taurine and magnesium in 41 WHO-CARDIAC study populations in the world. J Biomed Sci. Aug 2010;17(suppl 1):s21.
190. Hosseini S, Lee J, Sepulveda RT, Rohdewald P, Watson RR. A randomized, doubleblind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr Res. 2001;21(9):1251-1260.
191. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res. 2008:28(5):315-320.
192. Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive Patients. Lif Sci. 2004;74(7):855-862.
193. Van der Zwan LP, Scheffer PG, Teerlink T. Reduction of myeloperoxidase activity by melatonin and pycnogenol may contribute to their blood pressure lowering effect. Hypertension. 2010;56(3):e34-e35.
194. Cesarone MR, Belcaro G, Stuard S, et al. Kidney flow and function in hypertension: protective effects of pyconogenol in hypertensive particpants-a controlled study. J Cardiovasc Pharmacol Ther. 2010;15(1):41-46.
195. Taubert D, Roesen R, Schomig E. Effect of cocoa and tea intake on blood pressure: a meta-analysis. Arch Intern Med. 2007;167(7):626-634.
196. Grassi D, Lippi C, Necozione S, Desideri G, Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr. 2005;81(3):611-614.
197. Taubert D, Roesen R, Lehmann C, Jung N, Schomig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA. 2007;298(1):49-60.
198. Cohen DL, Townsend RR. Cocoa ingestion and hypertension-another cup please? J Clin Hypertens (Greenwich). 2007;9(8):647-648.
199. Ried K, Sullivan T, Fakler P, Frank OR, Stocks NP. Does chocolate reduce blood pressure? A meta-analysis. BMC Med. 2010;8:39-49.
200. Egan BM, Laken MA, Donovan JL, Woolson RF. Does dark chocolate have a role in the prevention and management of hypertension?: commentary on the evidence. Hypertension. 2010;55(6):1289-1295.
201. Desch S, Kobler D, Schmidt J, et al. Low vs. higher-dose dark chocolate and blood pressure in cardiovascular high-risk patients. Am J Hypertens. 2010;23(6):694-700.
202. Desch S, Schmidt J, Kobler D, et al. Effect of cocoa products on blood pressure: systematic review and meta-analysis. Am J Hypertens. 2010;23(1):97-103.
203. Grassi D, Desideri G, Necozione S, et al. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr. 2008;138(9):1671-1676.
204. Grassi D, Necozione S, Lippi C, et al. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension. 2005;46(2):398-405.
205. Sankar D, Sambandam G, Ramakrishna Rao M, Pugalendi KV. Modulation of blood pressure, lipid profiles and redox status in hypertensive patients taking different edible oils. Clin Chim Acta. 2005;355(1-2):97-104.
206. Sankar D, Rao MR, Sambandam G, Pugalendi KV. Effect of sesame oil on diuretics or beta-blockers in the modulation of blood pressure, anthropometry, lipid profile and redox status. Yale J Biol Med. 2006;79(1):19-26.
207. Miyawaki T, Aono H, Toyoda-Ono Y, Maeda H, Kiso Y, Moriyama K. Antihypertensive effects of sesamin in humans. J Nutr Sci Vitaminol (Toyko). 2009;55(1):87-91.
208. Wichitsranoi J, Weerapreeyakul N, Boonsiri P, et al. Antihypertensive and antioxidant effects of dietary black sesame meal in pre-hypertensive humans. Nutr J. Aug 2011;10:82.
209. Sudhakar B, Kalaiarasi P, Al-Numair KS, Chandramohan G, Rao RK, Pugalendi KV. Effect of combination of edible oils on blood pressure, lipid profile, lipid peroxidative markers, antioxidant status, and electrolytes in patients with hypertension on nifedipine treatment. Saudi Med J. 2011;32(4):379-385.
210. Sankar D, Rao MR, Sambandam G, Pugalendi KV. A pilot study of open label sesame oil in hypertensive diabetics. J Med Food. 2006;9(3):408-412.
211. Harikumar KB, Sung B, Tharakan ST, et al. Sesamin manifests chemopreventive effects through the suppression of NF-kappa-B-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res. 2010;8(5):751-761.
212. Nakano D, Ogura K, Miyakoshi M, et al. Antihypertensive effect of angiotensin I-converting enzyme inhibitory peptides from a sesame protein hydrolysate in spontaneously hypertensive rats. Biosci Biotechnol Biochem. 2006;70(5):1118-1126.
213. Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004;43(2):192-197.
214. Cavallo A, Daniels SR, Dolan LM, Khoury JC, Bean JA. Blood pressure response to melatonin in type 1 diabetes. Pediatr Diabetes. 2004;5(1):26-31.
215. Cavallo A, Daniels SR, Dolan LM, Bean JA, Khoury JC. Blood pressure-lowering effect of melatonin in type 1 diabetes. J Pineal Res. 2004;36(4):262-266.
216. Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, Volpe A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens. 2005;18(12, pt 1):1614-1618.
217. Grossman E, Laudon M, Yalcin R, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med. 2006;119(10):898-902.
218. Rechcinski T, Kurpesa M, Trzos E, Krzeminska-Pakula M. The influence of melatonin supplementation on circadian pattern of blood pressure in patients with coronary artery disease-preliminary report [in Polish]. Pol Arch Med Wewn. 2006;115(6):520-528.
219. Merkur'eva GA, Ryzhak GA. Effect of the pineal gland peptide preparation on the diurnal profile of arterial pressure in middle-aged and elderly women with ischemic heart disease and arterial hypertension [in Russian]. Adv Gerontol. 2008;21(1):132-142.
220. Zaslavskaia RM, Shcherban' EA, Logvinenko SI. Melatonin in combined therapy of patients with stable angina and arterial hypertension [in Russian]. Klin Med (Mosk). 2009:86(9):64-67.
221. Zamotaev IuN, Enikeev AKh, Kolomoets NM. The use of melaxen in combined therapy of arterial hypertension in subjects occupied in assembly line production [in Russian]. Klin Med (Mosk). 2009;87(6):46-49.
222. Rechcinski T, Trzos E, Wierzbowska-Drabik K, Krzeminska-Pakuta M, Kurpesa M. Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability. Hypertens Res. 2002;33(1):56-61.
223. Kozirog M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011;50(3):261-266.
224. Zeman M, Dulkova K, Bada V, Herichova I. Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile. Life Sci. 2005;76(16):1795-1803.
225. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press. 2003;12(1):19-24.
226. Simko F, Pechanova O. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. J Pineal Res. 2009;47(2):127-133.
227. Cui HW, Zhang ZX, Gao MT, Liu Y, Su AH, Wang MY. Circadian rhythm of melatonin and blood pressure changes in patients with essential hypertension [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2008;36(1):20-23.
228. Ostrowska Z, Kos-Kudla B, Marek B, et al. Circadian rhythm of melatonin in patients with hypertension [in Polish]. Pol Merkur Lekarski. 2004;17(97):50-54.
229. Shatilo VB, Bondarenko EV, Antoniuk-Shcheglova IA. Pineal gland melatoninproducing function in elderly patients with hypertensive disease: age peculiarities [in Russian]. Adv Gerontol. 2010;23(4):530-542.
230. Forman JP, Curhan GC, Schernhammer ES. Urinary melatonin and risk of incident hypertension among young women. J Hypertens. 2010;28(3):446-451.
231. Li HL, Kang YM, Yu L, Xu HY, Zhao H. Melatonin reduces blood pressure in rats with stress-induced hypertension via GABAA receptors. Clin Exp Pharmacol Physiol. 2009;36(4):436-440.
232. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res. 2007;42(4):319-322.
233. Irmak MK, Sizlan A. Essential hypertension seems to result from melatonin-induced epigenetic modifications in area postrema. Med Hypotheses. 2006;66(5):1000-1007.
234. De-Leersnyder H, de Blois MC, Vekemans M, et al. beta(1)-adrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith-Magenis syndrome. J Med Genet. 2001;38(9):586-590.
235. Watanabe T, Arai Y, Mitsui Y, et al. The blood pressure-lowering effect and safety of chlorogenic acid from green coffee bean extract in essential hypertension. Clin Exp Hypertens. 2006;28(5):439-449.
236. Ochiai R, Jokura H, Suzuki A, Tokimitsu I, et al. Green coffee bean extract improves human vasoreactivity. Hypertens Res. 2004;27(10):731-737.
237. Yamaguchi T, Chikama A, Mori K, et al. Hydroxyhydroquinone-free coffee: a double-blind, randomized controlled dose-response study of blood pressure. Nutr Metab Cardiovasc Dis. 2008;18(6):408-414.
238. Chen ZY, Peng C, Jiao R, Wong YM, Yang N, Huang Y. Anti-hypertensive nutraceuticals and functional foods. J Agric Food Chem. 2009;57(11):4485-4499.
239. Ochiai R, Chikama A, Kataoka K, et al. Effects of hydroxyhydroquinone-reduced coffee on vasoreactivity and blood pressure. Hypertens Res. 2009;32(11):969-974.
240. Kozuma K, Tsuchiya S, Kohori J, Hase T, Tokimitsu I. Antihypertensive effect of green coffee bean extract on mildly hypertensive subjects. Hypertens Res. 2005;28(9):711-718.
241. Palatini P, Ceolotto G, Ragazzo F, et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens. 2009;27(8):1594-1601
242. Hu G, Jousilahti P, Nissinen A, Bidel S, Antiainen R, Tuomilehto J. Coffee consumption and the incidence of antihypertensive drug treatment in Finnish men and women. Am J Clin Nutr. 2007;86(2):457-464.
243. Vlachopoulos CV, Vyssoulis GG, Alexopoulos NA, et al. Effect of chronic coffee consumption on aortic stiffness and wave reflections in hypertensive patients. Eur J Clin Nutr. 2007;61(6):796-802.
244. Morand C, Dubray C, Milenkovic D, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr. 2011;93(1):73-80.
245. Basu A, Penugonda K. Pomegranate juice: a heart-healthy fruit juice. Nutr Rev. 2009;67(1):49-56
246. Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004;23(3):423-433.
247. Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis. 2001;158(1):195-198.
248. Stowe CB. The effects of pomegranate juice consumption on blood pressure and cardiovascular health. Complement Ther Clin Pract. 2011;17(2):113-115.
249. Feringa HH, Laskey DA, Dickson JE, Coleman CI. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. J Am Diet Assoc. 2011;111(8):1173-1181.
250. Sivaprakasapillai B, Edirisinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism. 2009:58(12):1743-1746.
251. Edirisinghe I, Burton-Freeman B, and Tissa Kappagoda C. Mechanism of the endothelium-dependent relaxation evoked by a grape seed extract. Clin Sci (Lond). 2008;114(4):331-337.
252. Walker AF, Marakis G, Morris AP, Robinson PA. Promising hypotensive effect of hawthorn extract: a randomized double-blind pilot study of mild, essential hypertension. Phytother Res. 2002;16(1):48-54.
253. Walker AF, Marakis G, Simpson E, et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomized controlled trial. Br J Gen Pract. 2006;56(527):437-443.
254. Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. Am Fam Physician. 1991;44(5):1651-1658.
255. McCabe BJ, Frankel EH, Wolfe JJ, eds. Handbook of Food-Drug Interactions. Boca Raton, FL: CRC Press; 2003.
256. Houston MC. The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease. Ther Adv Cardiovasc Dis. 2010;4(3):165-183.